| Status | Study |
| Not yet recruiting |
Study Name: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients Condition: Antithrombin Deficiency Type 2 Date: 2017-03-21 Interventions: Drug: ATryn continuous infusion replenish serum thrombin levels |
| Recruiting |
Study Name: "Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects" Condition: Congenital Heart Diseases Conotruncal Defects Congenital D Date: 2015-07-13 Interventions: Other: none intervention |
| Recruiting |
Study Name: Atenativ Effect on Uterine Blood Flow and Preeclampsia Condition: Antithrombin III Deficiency Date: 2014-10-28 Interventions: Drug: Atenativ intravenous transfusion Other Name: a |
| Completed |
Study Name: Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery Condition: ATIII Deficiency Date: 2014-04-01 Interventions: Drug: Anti-thrombin III |
| Terminated |
Study Name: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery Condition: Thrombophilia Due to Acquired Antithrombin III Deficiency Date: 2012-02-07 Interventions: Drug: Recombinant antithrombin (rhAT) Subjects will receive an intravenous bolus of 500 units of recombi |
| Completed |
Study Name: A Study of KW-3357 in Congenital Antithrombin Deficiency Condition: Congenital Antithrombin Deficiency Date: 2009-07-10 Interventions: Drug: KW-3357 50IU/mL, IV single dose |
| Completed |
Study Name: Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass Condition: Acquired Antithrombin III Deficiency Coronary Artery Bypass Date: 2009-01-14 Interventions: Drug: Antithrombin III Single dose of antithrombin III sufficient to achieve a preoperative level of 120 |
| Recruiting |
Study Name: Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate. Condition: Antithrombin III Deficiency Date: 2006-04-26 Interventions: Drug: Plasma-derived AT-III concentrate Segment I: A singl |
| Completed |
Study Name: Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery Condition: Antithrombin III Deficiency Date: 2005-05-10 Interventions: Biological: Recombinant human antithrombin (rhAT) Up to 24 hours prior to the scheduled elective surgica |
| Completed |
Study Name: Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. Condition: Antithrombin Deficiency, Congenital Date: 2003-03-17 Interventions: Biological: Recombinant Human Antithrombin (rhAT) Biological/Vaccine: Recombinant human antithrombin(rhA |